Autogenous vaccines: determining product need and antigen selection, production and testing considerations.
It is estimated that in the 12-month period from May 1999--April 2000 approximately $16.06 million in swine autogenous vaccines were sold in the United States. Swine influenza and PRRS vaccines accounted for over one-half of these sales. Usage patterns suggest USDA regulation covering the production and use of autogenous vaccines may be violated. A proposal for product use and selection criteria that may minimize the potential for abuse of autogenous regulations is described. Using a decision tree, the analysis considers issues such as availability of registered products, recognized strain variations and the current state of vaccine technology. Proposed testing and production scenarios are described that include food safety considerations, yet allow for the rapid production and testing required for autogenous products.
Draayer
H A
HA
Pfizer Animal Health, Richland, MI 49083, USA. Hans_Draayer@groton.pfizer.com
D000941:Antigens / Q000096:biosynthesis / Q000302:isolation & purification*; D003663:Decision Trees; D006301:Health Services Needs and Demand; D014612:Vaccines
D000941:Antigens; D014612:Vaccines